TocilizuMab manufacturers
- Tocilizumab
-
- $0.00 / 1g
-
2025-04-27
- CAS:375823-41-9
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100G
- TocilizuMab
-
- $10.00 / 1KG
-
2025-04-23
- CAS:375823-41-9
- Min. Order: 100KG
- Purity: 99%
- Supply Ability: 100 mt
- TocilizuMab
-
- $0.00 / 1g
-
2024-09-25
- CAS:375823-41-9
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50kg
|
| | TocilizuMab Basic information |
| Product Name: | TocilizuMab | | Synonyms: | TocilizuMab;Actemra 200;R 1569;RoActemra;Tocilizumab,Atlizumab;anti-IL-6R Tocilizumab;Tocilizumab (anti-IL-6R);Tocilizumab-Actemra | | CAS: | 375823-41-9 | | MF: | C14H12O3 | | MW: | 0 | | EINECS: | 248-451-4 | | Product Categories: | API | | Mol File: | Mol File | ![TocilizuMab Structure]() |
| | TocilizuMab Chemical Properties |
| storage temp. | Store at -80°C | | solubility | Soluble in DMSO | | form | Liquid | | color | Colorless to light yellow |
| | TocilizuMab Usage And Synthesis |
| Uses | Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4]. | | Clinical Use | Interleukin inhibitor:
Treatment of rheumatoid arthritis in combination with methotrexate | | in vivo | Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3]. | Animal Model: | A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2] | | Dosage: | 1.0 mg/100 μL | | Administration: | Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks | | Result: | Led the volume of each metastatic focus significantly smaller. |
| Animal Model: | SCID mice with SAS cells[3] | | Dosage: | 100 μg/mL | | Administration: | Intraperitoneal injection;100 μg/mL; every 48 hours; 20days | | Result: | Suppressed the growth of advanced tumors. |
| | Drug interactions | Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant administration | | IC 50 | IL-6 | | Metabolism | Tocilizumab undergoes biphasic elimination from the circulation. The total clearance of tocilizumab is concentration-dependent and is the sum of the linear and non-linear clearance. The concentration-dependent non-linear clearance plays a major role at low tocilizumab concentrations. Once the non-linear clearance pathway is saturated, at higher tocilizumab concentrations, clearance is mainly determined by the linear clearance. | | References | [1] Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70. DOI:10.1074/jbc.M111.295758
[2] Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526. DOI:10.3390/ijms14010515
[3] Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34. DOI:10.1158/1078-0432.CCR-09-0287
[4] Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954. DOI:10.1016/j.ijantimicag.2020.105954 |
| | TocilizuMab Preparation Products And Raw materials |
|